GMP 2019 SYMPOSIUM : DMPK-centered approach to predict Drug Efficacy and Safety
- Non classé
This symposium* offers community members the opportunity on one hand to discover the current perspectives on PBPK applications in drug development and on the other hand learn and grow personally and collectively in becoming advanced PBPK modelers.
REGISTER NOW to meet the leaders in the field!
Flyer symposium PBPK_VF
*Event sponsored by the GIP Genopole
This year, the missions of the Scientific Committee will be not only to prepare the annual GMP Symposium (held on 16, 17 and 18 October 2019 in Lyon), but also to take part in the organization of webinars throughout the year.
Defining the scientific content of the sessions / webinars, identifying and contacting the appropriate speakers, as well as monitoring/chairing these sessions / webinars will be the main missions of the SC.
Usually, two 30-minute TC per month are required to discuss all together and ensure the coordination of all the actions, until the Symposium in October.
Should you be interested, feel free to send an email to email@example.com to ask for additional information or to apply before the 7th of December 2018. Beware! The number of places proposed to participate in this Scientific Committee is limited!
Come and join us !!!
“Le progrès nait de la diversité des cultures et de l’affirmation des personnalités”
Pierre Joliot-Curie (Biologiste)”
Marion Millet and Yann Courbebaisse
For the GMP’s Scientific Committee.
Reminder: registrations for annual GMP symposium, October 17-19, 2018, in Paris
Dear members and colleagues,
We would like to express our sincere thanks to those who have already signed up for the next GMP symposium.
We have decided to extend the early bird registration until September 7 so that most of you can benefit from the preferential rates.
Please find below the updated information.
Please click here to register for the GMP Symposium. You will need to use your personal identifier to login.
You will find the updated scientific program on our Website.
The 3-day course is a shortened version of the course which has been given for the last eight years by Prof Bernd Meibohm & Johan Gabrielsson in the United States, and it is organized in Europe for the third time under the aegis of AP2POP association.
During this course, you will be introduced to basic principles in the pharmacokinetic and pharmacodynamic evaluation of novel therapeutic proteins and hands-on exercises in the PK/PD evaluation of these compounds. Topics include target-mediated drug disposition, tissue and tumor penetration, first-in-human dose selection, immunogenicity, clinical pharmacology challenges, biosimilars, and drug-drug interactions. The target audience comprises pharmaceutical scientists from industry, academia and regulatory agencies with basic knowledge in PK and PKPD that would like to receive a comprehensive overview or refresher on the PK and PKPD of this class of compounds. Hands-on exercises will be performed individually and in small groups using simple software tools (no prior experience required).
Attendance and registration:
The attendance will be strictly limited to 35 participants, allowing nice interactions. As well, a limited number of spots have been reserved for academia and trainees for one third of the price.
For more detailed information on the preliminary course program, as well as on the registration process, please visit:
Looking forward to seeing you in Lyon!
The Course Directors
Bernd Meibohm, University of Tennessee & Johan Gabrielsson, Swedish University of Agricultural Sciences
The Local Organizers
Emilie Hénin and Christian Laveille, Calvagone & AP2POP
AP2POP, Association pour la Promotion de la Pharmacocinétique de Population
How to proceed?
1) click on the link: http://www.carrefour.fr/engagements/boucles-du-coeur/inscription
2) choose the project « Ligue contre le Cancer – Corse Sud »
3) click on « voter pour cette association »
4) then validate your vote by clicking on the link in the confirmation email.
Everyone can vote, once a day, until March 1st.
Thanks for your support.